ZENITH NEGOTIATING THREE-YEAR SUPPLY DEAL WITH SQUIBB

Executive Summary

ZENITH NEGOTIATING THREE-YEAR SUPPLY DEAL WITH SQUIBB for "selected" generic products to be sold under the SquibbMark label, Zenith announced in a June 18 press release. The disclosure was made at the Zenith annual shareholders meeting in Park Ridge, New Jersey, and repeated in the follow up press release. "The agreement is expected to include certain Zenith products that are currently on the market and others for which new drug applications are pending approval from the U.S. FDA," the release states. "The product to be manufactured for the SquibbMark label will be produced by Zenith in conformity with quality assurance and quality control procedures of Squibb, as is the case for any supplier." Zenith's most recent ANDA approvals include three oral cephalosporin products: cephadrine -- Squibb's Velocef and SmithKline's Anspor; cefadroxil -- Bristol-Myers Duricef and Ultracef; and cephalexin -- Lilly's Ceclor.